Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today new in vivo data from its R&D wound healing program confirming once again the potential of the IM technology platform for wound healing applications.
These data demonstrate two distinct effects of the IM fraction on wound healing. First, the IM fraction induces significant tissue ingrowth leading to an accelerated wound healing process. Tissue ingrowth was increased 2-fold compared with the neutral proteins control (P=0.001). Secondly, the IM fraction reduces scar formation and prevents hypertrophic scarring. This bioactivity appears to be associated with the presence of growth factors and peptides with immune modulatory properties as well as antimicrobial activities.
"These new data once again confirm the potential of IM platform to improve the wound healing process as well as scar remodelling. The bioactive properties of the IM platform suggest that once incorporated as a bioactive compound in a matrix or implant, the IM platform might accelerate the natural process of wound healing for burned patients or for other patients undergoing various surgeries" said Dr Charles Doillon, M.D., Ph.D., researcher at Centre de Recherche du Centre Hospitalier de l'Université Laval who is leading this project.
In 2008, Advitech has put in place an extensive R&D wound healing program to characterize specific fractions and to obtain toxicological data through in vitro and in vivo studies.
Wound healing does represent a significant opportunity for Advitech and should help the Corporation to rapidly diversify its products portfolio and this, ideally, in both pharmaceutical and cosmeceutical sectors.
ABOUT WOUND HEALING:
According to Epsicom Business Intelligence Ltd., the global wound care market totalled $7.2 billion in 2006, with a 10% growth rate. The market growth is fueled by the population ageing, the increased incidence of diabetes as well as the technological advancement and the introduction of more efficient and cost-effective therapies compared to conventional treatments.
ABOUT ADVITECH INC. www.advitech.com:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex® for the treatment of mild-to-moderate psoriasis.
Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L and IM technological platforms.